Suspendido

MACH15Moderate Alcohol and Cardiovascular Health Trial

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está evaluando

Alcohol

Otro
Quiénes están siendo reclutados

Enfermedades Cardiovasculares+2

+ Enfermedades del Sistema Endocrino

+ Diabetes Mellitus

A partir de 50 años
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Estudio de Prevención

Intervencional
Inicio del estudio: febrero de 2018
Ver detalles del protocolo

Resumen

Patrocinador PrincipalBeth Israel Deaconess Medical Center
Última actualización: 27 de enero de 2026
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 5 de febrero de 2018

Fecha en la que se inscribió al primer participante.

The Moderate Alcohol and Cardiovascular Health Trial (MACH15) is a multicenter, worldwide, randomized clinical trial of \~15 gm of alcohol daily versus abstention, using a balanced parallel design and single-blind assessment of all outcomes among approximately 7,800 participants aged 50 years and older with advanced cardiovascular risk. Intervention will average 6 years in duration with a common close-out date. Following recruitment and pre-screening, participants will attend a screening visit followed by a two-week abstention washout period, a baseline visit and randomization, and subsequent visits at 3 months, 6 months, 12 months, and then annually until close-out.

Título OficialModerate Alcohol and Cardiovascular Health Trial
NCT03169530
Patrocinador PrincipalBeth Israel Deaconess Medical Center
Última actualización: 27 de enero de 2026
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 103 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Estudio de Prevención

Los estudios de prevención buscan evitar que se desarrolle una enfermedad. A menudo incluyen a personas en riesgo y evalúan vacunas, cambios en el estilo de vida o medicamentos preventivos.


Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Cualquier sexo

Sexo biológico de los participantes elegibles para inscribirse.

A partir de 50 años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos no permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

Enfermedades CardiovascularesEnfermedades del Sistema EndocrinoDiabetes MellitusEnfermedades metabólicasEnfermedades Nutricionales y Metabólicas

Criterios

Inclusion Criteria: * Age ≥50 years at screening * Postmenopausal, defined as 12 consecutive months without menstruation * Not alcohol naïve, defined by having consumed at least one drink of alcohol in the past five years * High risk for the occurrence of a new cardiovascular disease event, defined as having any one of the following: 1. American Heart Association (AHA)/American College of Cardiology (ACC) Risk Score ≥15% within the past 24 months (among those without clinical or subclinical cardiovascular disease \[CVD\]) 2. Clinical CVD (more than 6 months prior to randomization), defined by: 1. Previous myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), carotid endarterectomy (CE), carotid stenting; 2. Peripheral artery disease (PAD) with revascularization; 3. Acute coronary syndrome with or without resting electrocardiogram (ECG) change, ECG changes on a graded exercise test (GXT), or positive cardiac imaging study; 4. Prior stroke documented on brain imaging or with a persistent deficit. 3. Subclinical CVD, confirmed in available medical records: 1. At least a 50% diameter stenosis of a coronary, carotid, or lower extremity artery; 2. Coronary artery calcium score ≥400 Agatston units; 3. Ankle brachial index (ABI) ≤0.90; 4. Left ventricular hypertrophy (LVH) by ECG (based on computer reading), echocardiogram report, or other cardiac imaging procedure report; 5. Abdominal aortic aneurysm (AAA) ≥5 cm with or without repair. Exclusion Criteria: * High alcohol consumption, defined by any one of the following: 1. Alcohol Use Disorders Identification Test (AUDIT) score \>5 at screening 2. Drinking, on average, \>7 alcoholic beverages/week during the past 6 months 3. Drinking 6 or more alcoholic beverages on one occasion during the past 6 months * Yale-Brown Obsessive Compulsive Scale-heavy drinking (Y-BOCS-hd) total score of ≥6 on questions 7, 8, and 10 * Cardiovascular disease event (MI, revascularization procedure, or stroke) within the 6 months prior to randomization * AHA Class III-IV heart failure * History of alcohol or substance abuse (medical record confirmed or self-reported history) * Other intolerance or allergy to alcohol * Dual antiplatelet therapy * History of gastric bypass surgery * Any serious chronic liver disease (e.g., active hepatitis B and C infections) or liver tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\] and gamma-glutamyl transpeptidase \[GGT\]) \>2 times the upper limit of the normal range using local standards * Personal history of any colon or liver cancer * Any other cancer with a life expectancy of less than 3 years * Diagnosed with breast cancer that required either surgery or removal of breast tissue or chemotherapy * Mother or sister ever diagnosed with breast cancer that required either surgery or removal of breast tissue or chemotherapy * Estimated glomerular filtration rate (eGFR) \<30 ml/min /1.73m2 or end-stage renal disease (ESRD) * Ongoing use of any medication for which alcohol consumption is contraindicated * A Patient Health Questionnaire (PHQ-9) ≥15 at screening * History of any organ transplant * Unintentional weight loss \>10% in last 6 months * Currently participating in another clinical trial (intervention trial) with CVD outcomes. Note: Participant must wait until the completion of his/her activities or the completion of the other trial before being screened for MACH15. Local restrictions for entry by participants can be more conservative if mandated. * Not willing or able to provide a name and contact information for at least one additional contact person other than self * Investigator discretion regarding appropriateness of participation or concern about intervention adherence, including: 1. moderate - severe psychiatric illness 2. behavioral concerns regarding likelihood of low adherence to trial protocol 3. a medical condition likely to limit survival to less than 3 years 4. advanced chronic disease, such as dementia, that requires 24-hour care * Not willing or able to provide a signed and dated informed consent form * Not willing or able to comply with all trial procedures.

Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Grupos de Tratamiento
Objetivos del Estudio

Un solo grupo de intervención está designado en este estudio

0% de probabilidad de ser asignado al grupo placebo

Grupos de Tratamiento

Grupo I

Comparador Activo
One standard serving of alcohol (\~15 gm) daily

Objetivos del Estudio

Objetivos Primarios

Objetivos Secundarios

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene 4 ubicaciones

Suspendido

Johns Hopkins ProHealth Clinical Research Center

Baltimore, United StatesAbrir Johns Hopkins ProHealth Clinical Research Center en Google Maps
Suspendido

Wake Forest Sticht Center on Aging

Winston-Salem, United States
Suspendido

Julius Clinical

Zeist, Netherlands
Suspendido

Center for Bioethics and Research

Ibadan, Nigeria
Suspendido4 Centros de Estudio